Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29510819 | 0.82 | GSK3B (0.40) | SCN9ARAB9ANPC1SMN1; SMN2GSK3B | |
| SCHEMBL21961534 | 0.82 | GSK3B (0.40) | SCN9ARAB9ANPC1SMN1; SMN2GSK3B | |
| SCHEMBL31497508 | 0.80 | MAOB (0.50) | SCN9ARAB9ANPC1SMN1; SMN2GSK3B | |
| SCHEMBL8709449 | 0.79 | L3MBTL1 (0.46) | RAB9ANPC1SMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL1609995 | 0.79 | CYP17A1 (0.40) | SCN9ARAB9ANPC1SMN1; SMN2GSK3B | |
| SCHEMBL29394473 | 0.78 | LCK (0.47) | RAB9ANPC1SMN1; SMN2GSK3BDYRK1A | |
| SCHEMBL30082722 | 0.77 | MAPT (0.35) | MEN1KMT2ANAMPT | |
| SCHEMBL21187 | 0.76 | KDM4E (0.47) | L3MBTL1 | |
| SCHEMBL23616433 | 0.76 | JAK3 (0.51) | GSK3BDYRK1A | |
| SCHEMBL1827089 | 0.75 | KDM4E (0.46) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016004417-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-07 | — | — | WO | disclosed |
| US-20160002204-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002204-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002204-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-07 | — | — | US | disclosed |
| CN-103724347-B | Method for extracting cytisine from thermopsis lanceolata | SICHUAN XIELI PHARMACEUTICAL CO LTD | 2015-07-22 | — | — | CN | disclosed |
| CN-103724347-A | Method for extracting cytisine from thermopsis lanceolata | SICHUAN XIELI PHARMACEUTICAL CO LTD | 2014-04-16 | — | — | CN | disclosed |
| US-20070167353-A1 | PRODRUG COMPOSITION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2007-07-19 | — | — | US | disclosed |
| US-20070167353-A1 | PRODRUG COMPOSITION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2007-07-19 | — | — | US | disclosed |
| US-6465650-B1 | INTERMEDIATE STEPS IN PREPARING PEPTIDE NUCLEIC ACIDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-10-15 | — | — | US | disclosed |
| EP-0672701-B1 | PNA-synthesis using a base labile aminoprotecting group | HOECHST AG (DE) | 1999-07-28 | — | — | EP | disclosed |
| EP-0672661-A1 | Substituted N-ethyl-glycinderivatives for the preparation of PNA and PNA-/DNA hybrides | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-09-20 | — | — | EP | disclosed |
| EP-0672701-A1 | PNA-synthesis using a base labile aminoprotecting group | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002204-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | SCN9A 1814/4885RAB9A 1960/4885NPC1 508/4885 |
| US-20070167353-A1 | PRODRUG COMPOSITION | ADA, SLC29A1, SLC29A2 | SCN9A 1438/4885RAB9A 533/4885NPC1 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.